28th Apr 2025 17:52
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Block Listing Six Monthly Return
LONDON AND PHILADELPHIA - April 28, 2025, Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
Name of applicant: | Avacta Group plc | |||
Name of scheme: | EMI scheme | |||
Period of return: | From: | 28 October 2024 | 27 April 2025 | |
Balance of unallotted securities under scheme(s) from previous return: | 275,380 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | nil | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 47,000 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 228,380 | |||
Name of applicant: | Avacta Group plc | ||||
Name of scheme: | LTIP/ESOS scheme | ||||
Period of return: | From: | 28 October 2024 | 27 April 2025 | ||
Balance of unallotted securities under scheme(s): | 5,913,257 | ||||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | nil | ||||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 4,366,882 | ||||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,546,375 | ||||
Name of contact: | Brian Hahn, Company Secretary | ||||
Telephone number of contact: | + 44 (0) 1904 217070 | ||||
Ends-
For further information from Avacta Group plc, please contact:
Avacta Group plc Michael Vinegrad, Group Communications Director | https://avacta.com/ |
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden
|
www.peelhunt.com
|
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers
ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert |
www.panmureliberum.com
|
Investor Contact Renee Leck THRUST Strategic Communications
|
|
Media Contact Carly Scaduto Carly Scaduto Consulting |
|
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
Related Shares:
Avacta Group